We are live on ! Find out more
CBPO

China Biologic Products Holdings, Inc.
CBPO

Delisted

CBPO was delisted on the 20th of April, 2021.

137 hedge funds and large institutions have $2.02B invested in China Biologic Products Holdings, Inc. in 2017 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 49 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

341% more call options, than puts

Call options by funds: $10.5M | Put options by funds: $2.37M

1% less capital invested

Capital invested by funds: $2.04B → $2.02B (-$15.7M)

4% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 26

4% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 49

4% less funds holding

Funds holding: 143137 (-6)

20% less funds holding in top 10

Funds holding in top 10: 54 (-1)

Holders
137
Holders Change
-6
Holders Change %
-4.2%
% of All Funds
3.41%
Holding in Top 10
4
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-20%
% of All Funds
0.1%
New
25
Increased
47
Reduced
49
Closed
26
Calls
$10.5M
Puts
$2.37M
Net Calls
+$8.09M
Net Calls Change
+$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
ProShare Advisors
76
ProShare Advisors
Maryland
$1.45M -$365K -3,419 -19%
OAM
77
Oxford Asset Management
United Kingdom
$1.45M +$1.55M +14,512 New
State Street
78
State Street
Massachusetts
$1.44M +$165K +1,541 +12%
Geode Capital Management
79
Geode Capital Management
Massachusetts
$1.43M +$204K +1,906 +15%
SG Americas Securities
80
SG Americas Securities
New York
$1.34M -$293K -2,741 -17%
Nordea Investment Management
81
Nordea Investment Management
Sweden
$1.32M +$189K +1,768 +15%
New York State Common Retirement Fund
82
New York State Common Retirement Fund
New York
$1.3M -$2.69M -25,199 -66%
DekaBank Deutsche Girozentrale
83
DekaBank Deutsche Girozentrale
Germany
$1.27M -$116K -1,090 -8%
Capstone Investment Advisors
84
Capstone Investment Advisors
New York
$1.16M +$706K +6,604 +131%
First Trust Advisors
85
First Trust Advisors
Illinois
$1.16M +$326K +3,053 +36%
CS
86
Credit Suisse
Switzerland
$1.08M -$5.58M -52,185 -83%
HLA
87
Hamilton Lane Advisors
Pennsylvania
$921K
Two Sigma Advisers
88
Two Sigma Advisers
New York
$891K +$951K +8,900 New
RFC
89
Regions Financial Corp
Alabama
$864K -$26.1K -244 -3%
Citigroup
90
Citigroup
New York
$738K -$15K -140 -2%
LPL Financial
91
LPL Financial
California
$735K +$55.1K +516 +8%
Northern Trust
92
Northern Trust
Illinois
$721K +$21.4K +200 +3%
SO
93
STRS Ohio
Ohio
$720K
D.E. Shaw & Co
94
D.E. Shaw & Co
New York
$612K -$23K -215 -3%
PM
95
Parametrica Management
Hong Kong
$598K +$638K +5,974 New
Jennison Associates
96
Jennison Associates
New York
$574K -$1.39K -13 -0.2%
CSS
97
Cubist Systematic Strategies
Connecticut
$517K +$530K +4,959 +2,480%
PG
98
PEAK6 Group
Illinois
$507K -$2.39M -22,319 -82%
GA
99
Gateway Advisory
New Jersey
$480K +$449K +4,200 New
Nomura Holdings
100
Nomura Holdings
Japan
$463K +$494K +4,623 New

CBPO Hedge Fund Activity: Q1 2017 in Review

137 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q1 2017, worth a combined $2.02B — down 0.77% from $2.04B a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of CBPO and 25 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 47 added.

The largest buyer was BlackRock, adding an estimated $141M. The largest seller was Capital World Investors, cutting an estimated $104M.

  • 137 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q1 2017, down from 143 in Q4 2016.
  • Funds reported $2.02B of China Biologic Products Holdings, Inc. stock for Q1 2017, down 0.77% quarter-over-quarter.
  • 25 funds opened new China Biologic Products Holdings, Inc. positions in Q1 2017 and 26 closed out, a net change of -1 holder.
  • The largest China Biologic Products Holdings, Inc. buyer in Q1 2017 was BlackRock, an estimated $141M added.
  • The largest China Biologic Products Holdings, Inc. seller in Q1 2017 was Capital World Investors, an estimated $104M sold.

Based on aggregated 13F filings for Q1 2017.